Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.86 USD | +0.54% | -11.43% | -36.95% |
May. 09 | BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 09 | Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Financials (USD)
Sales 2024 * | 3.75M | Sales 2025 * | 10.35M | Capitalization | 69.81M |
---|---|---|---|---|---|
Net income 2024 * | -108M | Net income 2025 * | -90M | EV / Sales 2024 * | 51.6 x |
Net Debt 2024 * | 124M | Net Debt 2025 * | 123M | EV / Sales 2025 * | 18.6 x |
P/E ratio 2024 * |
-0.68
x | P/E ratio 2025 * |
-0.97
x | Employees | 74 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.93% |
Latest transcript on BioXcel Therapeutics, Inc.
1 day | +0.54% | ||
1 week | -11.43% | ||
Current month | -26.19% | ||
1 month | -29.28% | ||
3 months | -43.98% | ||
6 months | -51.56% | ||
Current year | -36.95% |
Managers | Title | Age | Since |
---|---|---|---|
Vimal Mehta
FOU | Founder | 63 | 17-03-28 |
Director of Finance/CFO | 66 | 17-09-30 | |
Frank Yocca
CTO | Chief Tech/Sci/R&D Officer | 68 | 17-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Miller
BRD | Director/Board Member | 67 | 22-06-30 |
Peter Mueller
CHM | Chairman | 68 | 17-03-31 |
Sandeep Laumas
BRD | Director/Board Member | 56 | 17-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 9 M€ | +10.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 1.86 | +0.54% | 555,627 |
24-05-23 | 1.85 | -6.09% | 675,137 |
24-05-22 | 1.97 | -1.99% | 403,292 |
24-05-21 | 2.01 | -4.29% | 268,182 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.95% | 69.81M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.37% | 22.1B | |
-8.14% | 18.34B | |
-41.70% | 16.59B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- BTAI Stock